Patient with stable ischemic heart disease in Ukraine and Europe: The CLARIFY registry 5-year results

Main Article Content

M. I. Lutay
O. M. Parkhomenko
G. F. Lysenko
I. P. Golikova
N. Greenlaw
R. Ferrari
I. Ford
K. M. Fox
J. -C. Tardif
M. Tendera
Ph. G. Steg
R. Young


CLARIFY (The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) is a large multicenter project in the patients with a stable coronary artery disease (CAD). Within 5 years (2009–2014) 32,703 patients with confirmed diagnosis of CAD from 45 countries worldwide took part in the registry. Study results have demonstrated the significant differences between the current international standards of management and real-life clinical practice. Despite the fact that Ukrainian doctors actively used the complete list of the medicinal products recommended in the stable CAD (ASA, statins, BBs, ivabradine, ACE inhibitors), the control of therapy efficacy was very low and not only relative to the symptoms (after 5-year follow-up, angina attacks were persistent in 74 % of patients versus 16.9 % of the European patients). It should be noted that the clinical status of patients enrolled in Ukraine was more severe compared with the general group: 24.1 % of patients with the severe angina (ІІІ FC), in Europe – 2.2 %, in the world population – 1.6 %. Rate of the myocardial revascularization (surgical, endovascular) was very low in Ukraine as for 5-year study – only 5.9 %. As a result, our patients had 2-fold need in the hospitalization, 2-fold rate of fatal MI and acute cerebrovascular accidents (stroke + TIA) and 3-fold rate of the unstable angina. Control of such main risk factors of CAD, as BP levels < 140/90 mm Hg, LDL cholesterol levels < 1.8 mmol/L, HR < 70 beats per minute was insufficient both in the Ukrainian and global populations. During the study both Ukrainian and European patients have not demonstrated the dynamics in life style modification (majority of subjects continued sedentary lifestyle, were overweight, had signs of the abdominal obesity and smoked). Taking into consideration the results of the CLARIFY study, significant optimization of management of patients with stable CAD is still necessary.

Article Details


Patient with stable ischemic heart disease in Ukraine and Europe: The CLARIFY registry 5-year results


Kornatskyi V.M. Sertsevo-sudynna zakhvoriuvanist v Ukraini ta rekomendatsii shchodo pokrashchennia zdorov’ia v suchasnykh umovakh: Analitychno-statystychnyi posibnyk. К.,2012.117 p. (in Ukr.).

Lutai MI, Parkhomenko OM, Lysenko AF. Mezhdunarodnyy registr CLARIFY bolnykh so stabilnoy ishemicheskoy boleznyu serdtsa v Ukraine osobennosti problemy perspektivy. Ukrainskyi kardiolohichnyi zhurnal [Ukrainian J of Cardiology] 2013;3:13–21. (in Russ).

Kovalenkо VM, Lutai MI, Sirenkо YuM, Sychov OS. Sertsevo-sudynni zakhvoriuvannia. Klasyfikatsiia, standarty diahnostyky ta likuvannia. К.,2016.189p. (in Ukr.).

Stabilna ishemichna khvoroba sertsia (adaptovana klinichna nastanova, zasnovana na dokazakh). Arterialna hipertenziia [Arterial hypertension]. 2016;2(46):113–126.

2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J.– 2016;37(29):2315–2381.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J.2016;37(39):2999–3058

2014 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2014 (Advance Access published).– doi:

2013 ESC Guidelines on the management of stable coronary artery disease. Eur. Heart J. 2013;34:2949–3003.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J 2009;30(19):2337–2345.

Steg P, Ferrari R, Ford I, Greenlaw N, Tardif J-C, Tendera M, Abergel H, Fox KM, for the CLARIFY Investigators CLARIFY Investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease . PLoS One. 2012;7(5):36284.

Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM; Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the international observational CLARIFY registry. JAMA. 2014;174(10):1651–1659.

Most read articles by the same author(s)

1 2 3 > >>